

IN VITRO DIFFERENTIATION OF EMBRYONIC STEM CELLS INTO
CARDIAC-LIKE AND NEURONAL-LIKE CELLSINDUÇÃO DE DIFERENCIAÇÃO IN VITRO DE CÉLULAS-TRONCO EMBRIONÁRIAS EM
CÉLULAS DE TECIDO CARDÍACO E NERVOSO

Ana Helena da Rosa Paz^{1,2}, Ana Ayala Lugo^{2,3}, Paula Barros Terraciano², Luise Meurer^{1,4},
Eduardo Pandolfi Passos², Elizabeth Cirne Lima^{2,5}

ABSTRACT

Embryonic stem cells are pluripotent cell lines with the capacity of self-renewal and a broad differentiation plasticity. They are isolated from preimplantation embryos and can be cultured *in vitro* for long time without losing their pluripotency. Embryonic stem cells can also differentiate *in vitro* with the proper combination of growth and differentiation factors, cells will differentiate into more advanced stages of embryogenesis generating different adult cell type. In the present study, we induced the *in vitro* differentiation of mouse embryonic stem cells (line R1) into cardiomyocytes and neuronal cells. These differentiations were evaluated by reverse transcription-polymerase chain reaction to verify presence of tissue-specific markers.

Keywords: Embryonic stem cells, *in vitro* differentiation, embryonic stem cell culture.

RESUMO

Células-tronco embrionárias são linhagens celulares pluripotentes capazes de se multiplicar indefinidamente e com grande capacidade de diferenciação celular. São isoladas de embriões em estágio pré-implantacional e podem ser cultivadas por longo tempo em laboratório sem perder sua pluripotencialidade. Células-tronco embrionárias podem, ainda, se diferenciar *in vitro* através da adição de fatores de crescimento e diferenciação ao meio de cultivo. As células se diferenciarão em estágios mais avançados de embriogênese, gerando tipos diferentes de células adultas. No presente estudo, induzimos a diferenciação *in vitro* de células-tronco embrionárias de camundongos (linhagem R1) em células de tecido cardíaco e nervoso. A diferenciação foi avaliada pela reação em cadeia da polimerase precedida de transcrição reversa para verificar a presença de marcadores tecido-específicos.

Unitermos: Células-tronco embrionárias, diferenciação *in vitro*, cultivo de células-tronco embrionárias.

Rev HCPA 2008;28(2):96-100

Several systems are currently used to study differentiation of embryonic tissues, especially embryonic stem cells (ES). ES cells were isolated for the first time from uncommitted cells of the inner cell mass of preimplantation blastocysts (1,2). This cell line shows a rapid growth in culture and proliferates indefinitely (3). Propagated under specific growth conditions, they remain in an undifferentiated state (4,5). When implanted into blastocysts, the ES cells contribute efficiently to both somatic and germ-line tissues (6). Because of the ability to generate tissues from all the three primary germ layers, ES cells are called pluripotent cells. The possibility to manipulate ES cells *in vitro*, and to introduce targeted mutations by homologous recombination, (7) promoted the possibility to generate animal models for diseases. One promising use of ES cells is the possibility to differentiate these cells *in vitro*, and later use them as a source for

transplant. To achieve this aim, firstly ES cell lines have to be cultured in the presence of differentiation-inhibiting factors to maintain them in an uncommitted stage. These differentiation-inhibiting factors are provided by mitotically inactivated feeder cells, either embryonic fibroblasts (8), or by addition of leukemia inhibitory factor (LIF) to the culture medium (9). In contrast, ES cells can be stimulated to differentiate *in vitro* into different cell types by adding specific differentiation-inducing substances, e.g. retinoic acid (RA) or dimethyl sulfoxide (DMSO) (10,11).

To promote *in vitro* ES cell differentiation, first the ES cells must form a complex three-dimensional cell aggregate called embryoid bodies (EB). With the proper combination of growth and differentiation factors, cells within developing EB will differentiate into more advanced stages of embryogenesis, generating different adult cell types. In

1 Programa de Pós-Graduação: Ciências em Gastroenterologia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS.

2 Laboratório de Embriologia e Diferenciação Celular, Centro de Pesquisas do Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS.

3 Programa de Pós-Graduação em Genética e Biologia Molecular, UFRGS, Porto Alegre, RS.

4 Serviço de Anatomia Patológica e Citopatologia, HCPA, Porto Alegre, RS.

5 Faculdade de Veterinária, UFRGS, Porto Alegre, RS.

Correspondence: Laboratório de Embriologia e Diferenciação Celular, Centro de Pesquisas do Hospital de Clínicas de Porto Alegre. Rua Ramiro Barcelos, 2350. CEP: 90035-903. Porto Alegre, RS, Brasil. E-mail: anahpaz@gmail.com

the present study, we induced the *in vitro* differentiation of mouse ES cells (line R1) into cardiomyocytes and neuronal cells. These differentiations were evaluated by reverse transcription-polymerase chain reaction (RT-PCR) to verify presence of tissue-specific markers.

MATERIAL

Cells

Mouse ES cells line R1 (12) were used as the stem cell source for the experiment. Embryonic mouse fibroblasts were extracted from fetuses of a pregnant isogenic BALB/c mice with 15 days of pregnancy.

Undifferentiated ES cell culture conditions

Embryonic mouse fibroblasts (EMFI) treated with mitomycin C were used as feeder layer. The cell culture medium used was D-MEM (GIBCO) supplemented with 15% fetal calf serum, 1% antibiotic penicillin/streptomycin, 1% LIF and 1% non-essential amino acids (NEAA) (GIBCO). ES cells were maintained in these medium and incubated in a high-humidity, 37 °C incubator containing 5% CO₂ and 95% air. Every 48 hours they were split 1:3 with trypsin ethylene diaminetetraacetic acid (EDTA) 0,5% (GIBCO) solution.

In vitro differentiation induction protocols

EB were produced applying the hanging drop method (13). EB were maintained in bacteriological dishes (non-adherent) during 7 days in Iscove's medium enriched with 15% fetal calf serum, 1% NEAA, 1% penicillin/streptomycin solution. To induce *in vitro* differentiation of ES cells into cardiac cells, we added 1% DMSO during the first 2 days of the suspension culture. To obtain neuronal cells we added 10⁻⁷ M RA on the third, fourth and fifth days of the suspension culture. After the seventh day of suspension culture the cells were put in culture dishes (adhesion culture) and analyzed in 3, 7, 10, 13 and 16 days.

Molecular analysis

ES cell samples obtained from days 3, 7, 10, 13 and 16 of *in vitro* cell differentiation system were collected in lysis buffer (4M guanidinium thiocyanate, 0.1 M TRIS-HCl pH 7.5, 1% β-mercaptoethanol) and contained RNA were extracted by single step extraction method (14). In parallel RNA extracted from mouse cardiac and neuronal tissue were obtained in order to be a positive control for the molecular analysis. All mRNA was reverse transcribed and amplified using oligonucleotide primers complementary and identical

to the transcripts of the analyzed genes. The reverse transcription and amplification reactions were carried out with Tth-polymerase (Perkin Elmer, Norwalk, USA) following the protocol supplied by the manufacturer. β-tubulin was used as housekeeping gene and the designed primer (5'primer GGAACATAGCCGTAAACTGC- 3'primer'-TCACTGTGCCCTGAAACTTACC) was submitted to 63 °C of annealing temperature and 40 cycles in PCR reaction. To access ES cell differentiation to cardiac cells we searched for the expression of α-major histocompatibility complex (MHC) (15).

The products of the reverse transcription reactions were denatured, followed by 35 cycles of amplification (1-minute denaturation at 95 °C, 30-s annealing at 64 °C and 1-minute elongation at 72 °C). In contrast, to analyze the ES cell differentiation into neuronal cells, expression of NEURO 68 gene using specific primer (5'primer-GTTGGGAATAGGGCTCAATCT 3'primer-CCAGGAAGAGCAGACAGAGGT) was performed. The products of reverse transcription were denatured, followed by 40 cycles of amplification (1-minute denaturation at 95 °C, 30-s annealing at 63 °C and 1-minute elongation at 72 °C). Additionally, the expression of synaptophysin RNA was accessed using the following oligonucleotides primers (5' primer-GCCTGTCTCCTTGAACACGAAC 3'primer-TACCGAGAGAACAACAAAGGGC). PCR technique was conducted with 40 cycles of amplification (1-minute denaturation at 95 °C, 30-s annealing at 60 °C and 1-minute elongation at 72 °C). Products of RT-PCR reaction were submitted to a 2% agarose gel containing 0.35 μL of ethidium bromide and submitted to electrophoresis.

RESULTS AND DISCUSSION

Analysis of molecular biology results demonstrated the expression of β-tubulin in all mRNA analyzed samples. These data suggest that the RNA extraction method and the RT-PCR were successfully conducted.

The differentiation protocol applied to obtain cardiomyocytes from ES cells using 1% DMSO during the first 2 days of cell suspension culture demonstrated to be a simple, positive and low-cost method. Obtained cardiomyocytes presented *in vitro* morphological characteristics of cardiac tissue also expressed in the cardiac gene marker α-MHC (Figure 1) This gene encodes myosin heavy chain, a protein related to heart contraction function. It was also possible to detect a functional and physiological characteristic of cardiac tissue cells when cell cultures were analyzed by optical microscope. In addition, it was possible to observe differentiated

cardiomyocyte cluster cells promoting spontaneous contraction.




Figure 1 - Cardiac differentiation. A) Cardiac-like cell morphology after 7 days of embryonic stem differentiation protocol. In the selected area it was possible to observe spontaneous contractions resembling cardiac muscle cells. B) 2% agarose gel. Reverse transcription-polymerase chain reaction for myosin heavy chain. 1 - 100 bp DNA ladder; 2 - cDNA obtained from brain used as negative control; 3 - cDNA extracted from embryonic stem cell cultures without differentiation; 4 - cDNA obtained from differentiated embryonic stem cell (day 3); 5 - differentiated embryonic stem cells (day 7); 6 - differentiated embryonic stem cells (day 10); 7 - differentiated embryonic stem cells (day 13), 8 - differentiated embryonic stem cells (day 16); 9 - myosin gene positive control (cDNA extracted from mouse heart).

When ES cells were submitted to differentiation protocol to induce neuronal cell differentiation it was possible to observe a number of differentiated cells that showed neuronal-like morphological characteristics (Figure 2).




Figure 2 - Neurogenic differentiation. A) Neuronal-like cell morphology after 13 days of embryonic stem differentiation protocol. B) 1% agarose gel. Reverse transcription-polymerase chain reaction (RT-PCR) Neuro68 gene: 1 - DNA ladder 100 bp; 2 - negative control (cDNA from heart); 3 - embryonic stem cells without differentiation; 4 - differentiated embryonic stem cells (day 3); 5 - differentiated embryonic stem cells (day 7); 6 - differentiated embryonic stem cells (day 10); 7 - differentiated embryonic stem cells (day 13); 8 - differentiated ES cells (day 16); 9- positive control (cDNA obtained from mouse brain). C) 1% agarose gel. RT-PCR for synaptophysin gene: 1 - DNA ladder; 2 - embryonic stem cells without differentiation; 3 - differentiated embryonic stem cells (day 3), 4 - differentiated embryonic stem cells (day 7); 5 - differentiated embryonic stem cells (day 10); 6 - differentiated embryonic stem cells (day 13), 7 - differentiated embryonic stem cells (day 16); 8 - positive control (cDNA obtained from mouse brain).

In parallel to morphological analysis, neuronal-like cells also express the specific gene marker NEURO 68 (Figure 2). NEURO 68 gene

encodes a protein from the neurofilaments, exclusively expressed by neuronal cell types. Neuronal-like obtained cells also showed the expression of the

synaptophysin gene products, which encodes a synaptic vesicle glycoprotein with four transmembrane domains. It is present in neuroendocrine cells and in virtually all neurons in the brain and spinal cord that participate in synaptic transmission (Figure 2). The synaptophysin gene expression initiated on day 7 of culture and enhanced during the culture period to the 16th day. In addition, it is possible to observe that there was no detected synaptophysin expression on day 3 of ES cells cultured with the protocol to induce neuronal differentiation. The expression of NEURO 68 and synaptophysin genes clearly demonstrated the possibility of guiding embryonic cell differentiation from pluripotent cells to neuronal-like cells, considering that it was possible to observe neuronal morphology in addition to expression of neuronal-specific proteins.

ES cells can efficiently differentiate *in vitro* into cardiomyocytes or neuronal cells. This process of *in vitro* cell differentiation can be spontaneously observed in EB, but the generated population cells is a mix of several cell types. At the moment, there is no consensus on a protocol to induce a pure cell type culture from ES cells. Trying to answer this question, many protocols have been proposed to guide the ES cell differentiation into a defined cell type. By adding specific growth factors, it is possible to increase the rate of specific cell type. We followed protocols to induce ES cell differentiation preferentially into cardiac and neuronal cell types as described by other authors (10,13,16) in order to establish the ES cell *in vitro* differentiation routine in our laboratory.

Even with the possibility of *in vitro* differentiating ES cells, there are several challenges to ES cell research and therapy (17). Some researchers have reported that long cultures of human ES cell lines do not maintain normal karyotypes (18,19). Furthermore, the formation of teratomas is associated with the undifferentiated state of ES cells. To circumvent the risk of tumor formation, protocols leading to a 100% differentiation, or efficient purification selection should be used. Methods using cell surface markers and cell sorting have been successfully tested in animals (20). Another challenge in the use of ES for therapy is the potential immunogenicity of ES cell lineages.

In conclusion, although ES cells have the potential and (as data shown here) are relatively easy and cheap to *in vitro* differentiation, there are major challenges to overcome to employ ES cells therapy.

Acknowledgments

We would like to thank the Research Center at Hospital de Clínicas de Porto Alegre. This work was supported by CAPES, FINEP and FIPE.

REFERENCES

1. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. *Nature*. 1981;292(5819):154-6.
2. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci USA*. 1981;78(12):1441-5.
3. Bradley A. Embryonic stem cells: proliferation and differentiation. *Curr Opin Cell Biol*. 1990;2(6):1013-7.
4. Smith AG, Hooper ML. Buffalo rat liver cells produce a diffusible activity which inhibits the differentiation of murine embryonal carcinoma and embryonic stem cells. *Dev Biol*. 1987;121(1):1-9.
5. Wobus AM, Boheler KR. Embryonic stem cells: prospects for developmental biology and cell therapy. *Physiol Rev*. 2005;85(2):635-78.
6. Bradley A, Evans M, Kaufman MH, Robertson E. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. *Nature*. 1984;309(5965):255-6.
7. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. *Cell*. 1987;51(3):503-12.
8. Wobus AM, Holzhausen H, Jäkel P, Schöneich J. Characterization of a pluripotent stem cell line derived from a mouse embryo. *Exp Cell Res*. 1984;152(1):212-9.
9. Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, et al. Myeloid leukemia inhibitory factor maintains the developmental potential of embryonic stem cells. *Nature*. 1988;336(6200):684-7.
10. Wobus AM, Rohwedel J, Maltsev V, Hescheler J. *In vitro* differentiation of embryonic stem cells into cardiomyocytes or skeletal muscle cells is specifically modulated by retinoic acid. *Dev Genes Evolution*. 1994;204(1):36-45.
11. Fraichard A, Chassande O, Bilbaut G, Dehay C, Savatier P, Samarut J. *In vitro* differentiation of embryonic stem cells into glial cells and functional neuron. *J Cell Sci*. 1995;108(Pt 10):3181-8.
12. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. Derivation of completely cell culture-derived mice from early passage embryonic stem cells. *Proc Natl Acad Sci U S A*. 1993;90(18):8424-8.

13. Wobus AM, Hescheler J. [Development of an in vitro cardiomyocytes cell model for embryotoxicological and pharmacological studies]. *ALTEX*. 1992;9(2):29-42.
14. Chomczynski P, Sacchi N. Single-step method for RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem*. 1987;162(1):156-9.
15. Gulick J, Subramaniam A, Neumann J, Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. *J Biol Chem*. 1991;15;266(14):9180-5.
16. Strübing C, Wobus AM, Hescheler J. [Establishment of an in vitro model system for the differentiation of synaptically coupled neurons from mouse embryonic stem cells]. *ALTEX*. 1995;12(3):129-37.
17. Taupin P. Derivation of embryonic stem cells for cellular therapy: challenges and new strategies. *Med Sci Monit*. 2006;12(4):RA75-8.
18. Buzzard JJ, Gough NM, Crook JM, Colman A. Karyotype of Human ES cells during extended culture. *Nat Biotechnol*. 2004;22(4):381-2.
19. Maitra A, Arking DE, Shivapurkar N, Ikeda M, Stastny V, Kassaei K, et al. Genomic alterations in cultured human embryonic stem cells. *Nat Genet*. 2005;37(1):1099-103.
20. Menard C, Hagege AA, Agbulut O, Barro M, Morichetti MC, Brasselet C, et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. *Lancet*. 2005;366(9490):1005-12.

Recebido: 09/10/2007

Aceito: 23/06/2008